• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

New Drugs

Novel drugs approved by regulators for human use.
A drug is positioned as new if it:
  • offers treatment for a disease for which no specific therapy previously existed
  • targets a new therapeutic target
  • has a new mechanism of action
  • is developed in a new formulation, optimized or improved
  • is part of a new combination drug
  • belongs to a new class of drug compounds.
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory

Enjaymo: First Drug to Treat Cold Agglutinin Disease

by Julia Mardi February 9, 2022September 8, 2022

Sutimlimab will reduce the need for red blood cell transfusion due to hemolysis.

Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory

Tavneos: New Drug for ANCA-Associated Vasculitis

by Tanya von Reuss February 5, 2022September 8, 2022

Avacopan is better than prednisone in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.

Posted inNew Drugs, Oncology, Regulatory

Tivdak: New Drug for Cervical Cancer

by Tanya von Reuss February 3, 2022September 8, 2022

Tisotumab vedotin for therapy of previously treated recurrent or metastatic cervical cancer.

Posted inNew Drugs, Regulatory

Vabysmo: New Drug for Wet Age-Related Macular Degeneration and Diabetic Macular Edema

by Tanya von Reuss February 1, 2022September 8, 2022

Faricimab by Roche is a strong competitor to Eylea.

Posted inNew Drugs, Oncology, Rare/Orphan Diseases, Regulatory

Kimmtrak: Groundbreaking Immuno-Oncological Treatment for Metastatic Uveal Melanoma

by Tanya von Reuss January 27, 2022September 8, 2022

Tebentafusp is a pharmacological breakthrough in the fight against a deadly disease.

Posted inNew Drugs, Oncology, Rare/Orphan Diseases, Regulatory

Welireg: New Treatment for Tumors in Von Hippel–Lindau Disease

by Tanya von Reuss January 26, 2022September 8, 2022

Belzutifan by Merck & Co. is for the treatment of renal cell carcinoma, central nervous system hemangioblastomas, and pancreatic neuroendocrine tumors.

cough
Posted inNeuroscience, New Drugs, Regulatory

Lyfnua: First Drug for Refractory or Unexplained Chronic Cough

by Mark Gubar January 25, 2022September 8, 2022

Gefapixant will reduce cough frequency, thereby improving patients’ quality of life.

Posts pagination

Newer posts 1 … 5 6 7 8 9 … 13 Older posts
BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×